Review article: Anticancer role of PPARγ agonists in hematological malignancies found in the vasculature, marrow, and eyes

PPAR Research

Volumn , Issue , 2010, Pages

  Simpson Haidaris, P J ^a   Pollock, S J ^a   Ramon, S ^a   Guo, N ^a   Woeller, C F ^a   Feldon, S E ^a   Phipps, R P ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 15 HYDROXYICOSATETRAENOIC ACID; 2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 9 HYDROXYOCTADECADIENOIC ACID; BARDOXOLONE; BARDOXOLONE METHYL; BEVACIZUMAB; BORTEZOMIB; CIGLITAZONE; ESSENTIAL FATTY ACID; FENOPROFEN; FLUFENAMIC ACID; IBUPROFEN; INDOMETACIN; LINOLEIC ACID; LYSOPHOSPHATIDIC ACID; MICRORNA; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NITROLINOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROSTAGLANDIN D2; RANIBIZUMAB; ROSIGLITAZONE; TROGLITAZONE; TZD 18; UNCLASSIFIED DRUG;

ANGIOGENESIS; AUTOCRINE EFFECT; BONE MARROW; CANCER STEM CELL THEORY; CANCER THERAPY; CYTOLOGY; DISEASE ASSOCIATION; DORMANCY; EYE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MODULATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OCULAR LYMPHOMA; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIGNAL TRANSDUCTION; THEORY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; VASCULARIZATION;

EID: 77957241136     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2010/814609     Document Type: Review

References (399)

1. D.J. Mangelsdorf, C. Thummel, M. Beato, et al., "The nuclear receptor super-family: the second decade, " Cell, vol. 83, no. 6, pp. 835-839, 1995.
2. M. A. Lazar, "PPARγ, 10 years later, " Biochimie, vol. 87, no. 1, pp. 9-13, 2005.
3. T. M. Garcia-Bates, G. M. Lehmann, P. J. Simpson-Haidaris, S. H. Bernstein, P. J. Sime, and R. P. Phipps, "Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies, " PPAR Research, vol. 2008, Article ID 834612, 18 pages, 2008.
4. I. Goldenberg, M. Benderly, and U. Goldbourt, "Update on the use of fibrates: focus on bezafibrate, " Vascular Health and Risk Management, vol. 4, no. 1, pp. 131-141, 2008. (Pubitemid 351460854)
5. A. M. Sharma and B. Staels, "Review: peroxisome proliferator- activated receptor γ and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism, " Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 2, pp. 386-395, 2007.
6. J. L. Evans, J. J. Lin, and I. D. Goldfine, "Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARα, PPARγ, and PPARδ, " Current Diabetes Reviews, vol. 1, no. 3, pp. 299-307, 2005.
7. P. Meerarani, J. J. Badimon, E. Zias, V. Fuster, and P. R. Moreno, "Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications, " Current Molecular Medicine, vol. 6, no. 5, pp. 501-514, 2006.
8. I. Palomo, M. Alarcon, R. Moore-Carrasco, and J. M. Argiles, "Hemostasis alterations in metabolic syndrome (review), " International Journal ofMolecularMedicine, vol. 18, no. 5, pp. 969-974, 2006.
9. B. Staels, "PPAR agonists and the metabolic syndrome, " Therapie, vol. 62, no. 4, pp. 319-326, 2007. (Pubitemid 351211747)
10. M. A. Jay and J. Ren, "Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus, " Current Diabetes Reviews, vol. 3, no. 1, pp. 33-39, 2007. (Pubitemid 46592792)
11. R. S. Rosenson, "Fenofibrate: treatment of hyperlipidemia and beyond, " Expert Review of Cardiovascular Therapy, vol. 6, no. 10, pp. 1319-1330, 2008.
12. S. Saika, O. Yamanaka, Y. Okada, et al., "Effect of overexpression of PPARγ on the healing process of corneal alkali burn in mice, " American Journal of Physiology, vol. 293, no. 1, pp. C75-C86, 2007. (Pubitemid 47105026)
13. L. Michalik, B. Desvergne, N. S. Tan, et al., "Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice, " Journal of Cell Biology, vol. 154, no. 4, pp. 799-814, 2001. (Pubitemid 34292961)
14. R. Zhang and F. Zheng, "PPAR-γ and aging: one link through klotho?" Kidney International, vol. 74, no. 6, pp. 702-704, 2008.
15. M. S. Sulistio, A. Zion, N. Thukral, and R. Chilton, "PPARγ agonists and coronary atherosclerosis, " Current Atherosclerosis Reports, vol. 10, no. 2, pp. 134-141, 2008.
16. L. Villacorta, F. J. Schopfer, J. Zhang, B. A. Freeman, and Y. E. Chen, "PPARγ and its ligands: therapeutic implications in cardiovascular disease, " Clinical Science, vol. 116, no. 3, pp. 205-218, 2009.
17. H. Duez, J.-C. Fruchart, and B. Staels, "PPARs in inflammation, atherosclerosis and thrombosis, " Journal of Cardiovascular Risk, vol. 8, no. 4, pp. 187-194, 2001. (Pubitemid 32803672)
18. D. M. Ray, S. L. Spinelli, J. J. O'Brien, N. Blumberg, and R. P. Phipps, "Platelets as a novel target for PPARγ ligands: implications for inflammation, diabetes, and cardiovascular disease, " BioDrugs, vol. 20, no. 4, pp. 231-241, 2006. (Pubitemid 44050431)
19. S. L. Spinelli, J. J. O'Brien, S. Bancos, et al., "The PPARplatelet connection: modulators of inflammation and potential cardiovascular effects, " PPAR Research, vol. 2008, Article ID 328172, 16 pages, 2008.
20. F. Akbiyik, D. M. Ray, K. F. Gettings, N. Blumberg, C. W. Francis, and R. P. Phipps, "Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes, " Blood, vol. 104, no. 5, pp. 1361-1368, 2004. (Pubitemid 39166512)
21. Z. Cao and Y. Zhou, "Thiazolidinediones may be effective in the prevention of stent thrombosis with DES, " Medical Hypotheses, vol. 70, no. 2, pp. 329-332, 2008.
22. X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, "Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo, " Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116-9121, 1999. (Pubitemid 29164719)
23. A. Margeli, G. Kouraklis, and S. Theocharis, "Peroxisome proliferator activated receptor-γ (PPAR-γ) ligands and angiogenesis, " Angiogenesis, vol. 6, no. 3, pp. 165-169, 2003. (Pubitemid 38506661)
24. V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford, "PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer, " Neoplasia, vol. 7, no. 3, pp. 294-301, 2005. (Pubitemid 40411641)
25. D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, "PPARγ as a therapeutic target for tumor angiogenesis and metastasis, " Cancer Biology and Therapy, vol. 4, no. 7, pp. 687-693, 2005. (Pubitemid 41351164)
26. L. Piqueras, A. R. Reynolds, K. M. Hodivala-Dilke, et al., "Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 63-69, 2007. (Pubitemid 46370477)
27. A. Aljada, L. O'Connor, Y.-Y. Fu, and S. A. Mousa, "PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF-and VEGF-mediated angiogenesis, " Angiogenesis, vol. 11, no. 4, pp. 361-367, 2008.
28. F. Biscetti, E. Gaetani, A. Flex, et al., "Selective activation of peroxisome proliferator-activated receptor (PPAR)α and PPARγ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism, " Diabetes, vol. 57, no. 5, pp. 1394-1404, 2008.
29. P. Fraisl, M. Baes, and P. Carmeliet, "Hungry for blood vessels: linking metabolism and angiogenesis, " Developmental Cell, vol. 14, no. 3, pp. 313-314, 2008.
30. P.-H. Huang, M. Sata, H. Nishimatsu, M. Sumi, Y. Hirata, and R. Nagai, "Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice, " Biomedicine and Pharmacotherapy, vol. 62, no. 1, pp. 46-52, 2008.
31. E.-H. Kim and Y.-J. Surh, "The role of 15-deoxy-δ12, 14-prostaglandin J2, an endogenous ligand of peroxisome proliferator-activated receptor γ, in tumor angiogenesis, " Biochemical Pharmacology, vol. 76, no. 11, pp. 1544-1553, 2008.
32. Y.-W. Dong, X.-P. Wang, and K. Wu, "Suppression of pancreatic carcinoma growth by activating peroxisome proliferatoractivated receptor γ involves angiogenesis inhibition, " World Journal of Gastroenterology, vol. 15, no. 4, pp. 441-448, 2009.
33. D. Panigrahy, A. Kaipainen, S. Huang, et al., "PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 3, pp. 985-990, 2008. (Pubitemid 351282068)
34. S. Han and J. Roman, "Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics?" Anti-Cancer Drugs, vol. 18, no. 3, pp. 237-244, 2007. (Pubitemid 46192975)
35. C. Giaginis, A. Tsantili-Kakoulidou, and S. Theocharis, "Peroxisome proliferator-activated receptor-γ ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer, " PPAR Research, vol. 2008, Article ID 431763, 12 pages, 2008.
36. J. Roman, "Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy, " Journal of Investigative Medicine, vol. 56, no. 2, pp. 528-533, 2008.
37. D. Wang and R. N. DuBois, "Peroxisome proliferatoractivated receptors and progression of colorectal cancer, " PPAR Research, vol. 2008, Article ID 931074, 7 pages, 2008.
38. Y.-M. Zhou, Y.-H. Wen, X.-Y. Kang, H.-H. Qian, J.-M. Yang, and Z.-F. Yin, "Troglitazone, a peroxisome proliferatoractivated receptor γ ligand, induces growth inhibition and apoptosis of HepG2human liver cancer cells, " World Journal of Gastroenterology, vol. 14, no. 14, pp. 2168-2173, 2008.
39. J. D. Burton, D. M. Goldenberg, and R. D. Blumenthal, "Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types, " PPAR Research, vol. 2008, Article ID 494161, 7 pages, 2008.
40. D. Bonofiglio, S. Gabriele, S. Aquila, et al., "Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells, " Breast Cancer Research and Treatment, vol. 113, no. 3, pp. 423-434, 2009.
41. T. Inamoto, J. B. Shah, and A. M. Kamat, "Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer, " Urologic Oncology, vol. 27, no. 6, pp. 585-591, 2009.
42. S. A. Kliewer, S. S. Sundseth, S. A. Jones, et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318-4323, 1997. (Pubitemid 27194239)
43. T. Westendorf, J. Graessler, and S. Kopprasch, "Hypochloriteoxidized low-density lipoprotein upregulates CD36 and PPARγ mRNA expression and modulates SR-BI gene expression in murine macrophages, " Molecular and Cellular Biochemistry, vol. 277, no. 1-2, pp. 143-152, 2005. (Pubitemid 41236197)
44. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ), " Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953-12956, 1995.
45. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, "Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs, " Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406-3410, 1997.
46. Y. Wang, W. W. Porter, N. Suh, et al., "A synthetic triterpenoid, 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferatoractivated receptor γ, "Molecular Endocrinology, vol. 14, no. 10, pp. 1550-1556, 2000.
47. D. M. Ray, K. M. Morse, S. P. Hilchey, et al., "The novel triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large Bcell lymphoma cells through a peroxisome proliferatoractivated receptor gamma-independent pathway, " Experimental Hematology, vol. 34, no. 9, pp. 1202-1211, 2006.
48. D. M. Ray, F. Akbiyik, and R. P. Phipps, "The peroxisome proliferator-activated receptor γ (PPARγ) ligands 15-deoxy-δ12, 14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARγ-independent mechanisms, " Journal of Immunology, vol. 177, no. 8, pp. 5068-5076, 2006. (Pubitemid 44527577)
49. H. E. Ferguson, A. Kulkarni, G. M. Lehmann, et al., "Electrophilic peroxisome proliferator-activated receptor-γ ligands have potent antifibrotic effects in human lung fibroblasts, " American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 6, pp. 722-730, 2009.
50. A. E. Place, N. Suh, C. R. Williams, et al., "The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo, " Clinical Cancer Research, vol. 9, no. 7, pp. 2798-2806, 2003. (Pubitemid 36842126)
51. S. Wei, J. Yang, S.-L. Lee, S. K. Kulp, and C.-S. Chen, "PPARγ-independent antitumor effects of thiazolidinediones, " Cancer Letters, vol. 276, no. 2, pp. 119-124, 2009.
52. J. M. Adams and A. Strasser, "Is tumor growth sustained by rare cancer stem cells or dominant clones?" Cancer Research, vol. 68, no. 11, pp. 4018-4021, 2008.
53. A. L. Allan, S. A. Vantyghem, A. B. Tuck, and A. F. Chambers, "Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis, " Breast Disease, vol. 26, no. 1, pp. 87-98, 2006. (Pubitemid 46655481)
54. J. Rak, C. Milsom, and J. Yu, "Vascular determinants of cancer stem cell dormancy-do age and coagulation system play a role?" Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 116, no. 7-8, pp. 660-676, 2008.
55. L. Li and W. B. Neaves, "Normal stem cells and cancer stem cells: the niche matters, " Cancer Research, vol. 66, pp. 4553-4557, 2006.
56. M. H. Tomasson, "Cancer stem cells: a guide for skeptics, " Journal of Cellular Biochemistry, vol. 106, no. 5, pp. 745-749, 2009.
57. J. M. Rosen and C. T. Jordan, "The increasing complexity of the cancer stem cell paradigm, " Science, vol. 324, no. 5935, pp. 1670-1673, 2009.
58. M. L. Guzman and C. T. Jordan, "Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology, " Cancer Cell, vol. 15, no. 4, pp. 252-254, 2009.
59. W. A. Woodward, R. G. Bristow, M. F. Clarke, et al., "Radiation therapy oncology group translational research program stem cell symposiumml: incorporating stem cell hypotheses into clinical trials, " International Journal of Radiation Oncology Biology Physics, vol. 74, no. 5, pp. 1580-1591, 2009.
60. W. A. Woodward and E. P. Sulman, "Cancer stem cells: markers or biomarkers?" Cancer and Metastasis Reviews, vol. 27, no. 3, pp. 459-470, 2008.
61. W. Chearwae and J. J. Bright, "PPARγ agonists inhibit growth and expansion of CD133+ brain tumour stem cells, " British Journal of Cancer, vol. 99, no. 12, pp. 2044-2053, 2008.
62. M. Saiki, Y. Hatta, T. Yamazaki, et al., "Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells, " International Journal of Oncology, vol. 29, no. 2, pp. 437-443, 2006.
63. C. T. Jordan, "The leukemic stem cell, " Best Practice and Research in Clinical Haematology, vol. 20, no. 1, pp. 13-18, 2007.
64. J. Folkman, "Angiogenesis: an organizing principle for drug discovery?" Nature Reviews Drug Discovery, vol. 6, no. 4, pp. 273-286, 2007. (Pubitemid 46505878)
65. G. P. van Nieuw Amerongen, P. Koolwijk, A. Versteilen, and V. W. M. Van Hinsbergh, "Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 211-217, 2003. (Pubitemid 36231930)
66. V. W. M. van Hinsbergh and P. Koolwijk, "Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead, " Cardiovascular Research, vol. 78, no. 2, pp. 203-212, 2008. (Pubitemid 351556093)
67. J. A. Nagy and D. R. Senger, "VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype, " Experimental Cell Research, vol. 312, no. 5, pp. 538-548, 2006. (Pubitemid 43290331)
68. D. C. Darland and P. A. D'Amore, "Blood vessel maturation: vascular development comes of age, " Journal of Clinical Investigation, vol. 103, no. 2, pp. 157-158, 1999. (Pubitemid 29053132)
69. H. F. Dvorak, L. F. Brown, M. Detmar, and A. M. Dvorak, "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, " American Journal of Pathology, vol. 146, no. 5, pp. 1029-1039, 1995.
70. L. E. Benjamin, D. Golijanin, A. Itin, D. Pode, and E. Keshet, "Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal, " Journal of Clinical Investigation, vol. 103, no. 2, pp. 159-165, 1999. (Pubitemid 29053133)
71. J. L. Hatton and L. D. Yee, "Clinical use of PPARγ ligands in cancer, " PPAR Research, vol. 2008, Article ID 159415, 13 pages, 2008.
72. C. J. Robinson and S. E. Stringer, "The splice variants of vascular endothelial growth factor (VEGF) and their receptors, " Journal of Cell Science, vol. 114, no. 5, pp. 853-865, 2001. (Pubitemid 32273121)
73. H. Gille, J. Kowalski, B. Li, et al., "Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptorspecific vascular endothelial growth factor mutants, " Journal of Biological Chemistry, vol. 276, no. 5, pp. 3222-3230, 2001.
74. P. Koolwijk, E. Peters, B. van Der Vecht, et al., "Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro, " Angiogenesis, vol. 4, no. 1, pp. 53-60, 2001. (Pubitemid 34032037)
75. A. Sahni, M. T. Arevalo, S. K. Sahni, and P. J. Simpson-Haidaris, "The VE-cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells, " International Journal of Cancer, vol. 125, no. 3, pp. 577-584, 2009.
76. V. Joukov, K. Pajusola, A. Kaipainen, et al., "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases, " EMBO Journal, vol. 15, no. 2, pp. 290-298, 1996. (Pubitemid 26029207)
77. B. K. McColl, M. E. Baldwin, S. Roufail, et al., "Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D, " Journal of Experimental Medicine, vol. 198, no. 6, pp. 863-868, 2003. (Pubitemid 37152923)
78. S. Hirakawa, L. F. Brown, S. Kodama, K. Paavonen, K. Alitalo, and M. Detmar, "VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites, " Blood, vol. 109, no. 3, pp. 1010-1017, 2007. (Pubitemid 46220646)
79. S. Lee, T. T. Chen, C. L. Barber, et al., "Autocrine VEGF signaling is required for vascular homeostasis, " Cell, vol. 130, no. 4, pp. 691-703, 2007. (Pubitemid 47268059)
80. H.-P. Gerber, A. K. Malik, G. P. Solar, et al., "VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism, " Nature, vol. 417, no. 6892, pp. 954-958, 2002. (Pubitemid 34716872)
81. T.-H. Lee, S. Seng, M. Sekine, et al., "Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1, " PLoS Medicine, vol. 4, no. 6, article e186, pp. 1101-1116, 2007. (Pubitemid 46998627)
82. R. Masood, J. Cai, T. Zheng, D. L. Smith, Y. Naidu, and P. S. Gill, "Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDSKaposi sarcoma, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 3, pp. 979-984, 1997. (Pubitemid 27074433)
83. R. Masood, J. Cai, T. Zheng, D. Lynne Smith, D. R. Hinton, and P. S. Gill, "Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors, " Blood, vol. 98, no. 6, pp. 1904-1913, 2001.
84. J. M. Vieira, S. C. Rosa Santos, C. Espadinha, et al., "Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop, " European Journal of Endocrinology, vol. 153, no. 5, pp. 701-709, 2005. (Pubitemid 41672417)
85. S. Dias, K. Hattori, Z. Zhu, et al., "Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration, " Journal of Clinical Investigation, vol. 106, no. 4, pp. 511-521, 2000. (Pubitemid 30666384)
86. H. Zhang, Y. Li, H. Li, et al., "Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2, " Leukemia and Lymphoma, vol. 45, no. 9, pp. 1887-1897, 2004. (Pubitemid 38997158)
87. S. C. R. Santos and S. Dias, "Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways, " Blood, vol. 103, no. 10, pp. 3883-3889, 2004. (Pubitemid 38596309)
88. L. M. Ellis and D. J. Hicklin, "VEGF-targeted therapy: mechanisms of anti-tumour activity, " Nature Reviews Cancer, vol. 8, no. 8, pp. 579-591, 2008.
89. M. Mendoza and C. Khanna, "Revisiting the seed and soil in cancer metastasis, " International Journal of Biochemistry and Cell Biology, vol. 41, no. 7, pp. 1452-1462, 2009.
90. H. M. McGettrick, A. Filer, G. E. Rainger, C. D. Buckley, and G. B. Nash, "Modulation of endothelial responses by the stromal microenvironment: effects on leucocyte recruitment, " Biochemical Society Transactions, vol. 35, no. 5, pp. 1161-1162, 2007. (Pubitemid 350206450)
91. G. Lorusso and C. Ruegg, "The tumor microenvironment and its contribution to tumor evolution toward metastasis, " Histochemistry and Cell Biology, vol. 130, no. 6, pp. 1091-1103, 2008.
92. D. G. DeNardo, M. Johansson, and L.M. Coussens, "Immune cells as mediators of solid tumor metastasis, " Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 11-18, 2008.
93. T. D. Tlsty and L. M. Coussens, "Tumor stroma and regulation of cancer development, " Annual Review of Pathology, vol. 1, pp. 119-150, 2006.
94. O. De Wever, P. Demetter, M. Mareel, and M. Bracke, "Stromal myofibroblasts are drivers of invasive cancer growth, " International Journal of Cancer, vol. 123, no. 10, pp. 2229-2238, 2008.
95. W.-W. Lin and M. Karin, "A cytokine-mediated link between innate immunity, inflammation, and cancer, " Journal of Clinical Investigation, vol. 117, no. 5, pp. 1175-1183, 2007. (Pubitemid 46718402)
96. S. Ulisse, E. Baldini, S. Sorrenti, and M. D'Armiento, "The urokinase plasminogen activator systemml: a target for anticancer therapy, " Current Cancer Drug Targets, vol. 9, no. 1, pp. 32-71, 2009.
97. E. I. Deryugina and J. P. Quigley, "Matrix metalloproteinases and tumor metastasis, " Cancer and Metastasis Reviews, vol. 25, no. 1, pp. 9-34, 2006. (Pubitemid 43723979)
98. D. Ribatti, "Endogenous inhibitors of angiogenesis. A historical review, " Leukemia Research, vol. 33, no. 5, pp. 638-644, 2009.
99. F. Mbeunkui and D. J. Johann Jr., "Cancer and the tumor microenvironment: a review of an essential relationship, " Cancer Chemotherapy and Pharmacology, vol. 63, no. 4, pp. 571-582, 2009.
100. E. Hanna, J. Quick, and S. K. Libutti, "The tumour microenvironment: a novel target for cancer therapy, " Oral Diseases, vol. 15, no. 1, pp. 8-17, 2009.
101. G. Chometon and V. Jendrossek, "Targeting the tumour stroma to increase efficacy of chemo-and radiotherapy, " Clinical and Translational Oncology, vol. 11, no. 2, pp. 75-81, 2009.
102. K. Anton and J. Glod, "Targeting the tumor stroma in cancer therapy, " Current Pharmaceutical Biotechnology, vol. 10, no. 2, pp. 185-191, 2009.
103. A. L. Bauer, T. L. Jackson, and Y. Jiang, "Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis, " PLoS Computational Biology, vol. 5, no. 7, article e1000445, 2009.
104. V. Baud and M. Karin, "Is NF-κB a good target for cancer therapy? Hopes and pitfalls, " Nature Reviews Drug Discovery, vol. 8, no. 1, pp. 33-40, 2009.
105. W. E. Naugler and M. Karin, "The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer, " Trends inMolecularMedicine, vol. 14, no. 3, pp. 109-119, 2008.
106. M. Karin, "The IκB kinase-a bridge between inflammation and cancer, " Cell Research, vol. 18, no. 3, pp. 334-342, 2008.
107. S. Aboudola and A. R. Kini, "Angiogenesis in lymphoproliferative disorders: a therapeutic target?" Current Opinion in Hematology, vol. 12, no. 4, pp. 279-283, 2005. (Pubitemid 41058391)
108. Y. Bao, R. Li, J. Jiang, et al., "Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway, " Molecular and Cellular Biochemistry, vol. 317, no. 1-2, pp. 189-196, 2008.
109. F. Spinella, E. Garrafa, V. D. Castro, et al., "Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade, " Cancer Research, vol. 69, no. 6, pp. 2669-2676, 2009.
110. J. Knowles, M. Loizidou, and I. Taylor, "Endothelin-1 and angiogenesis in cancer, " Current Vascular Pharmacology, vol. 3, no. 4, pp. 309-314, 2005. (Pubitemid 41264282)
111. A. Grothey and L. M. Ellis, "Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies, " Cancer Journal, vol. 14, no. 3, pp. 170-177, 2008.
112. T. Shih and C. Lindley, "Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies, " Clinical Therapeutics, vol. 28, no. 11, pp. 1779-1802, 2006. (Pubitemid 46038527)
113. X. Dong, Z. C. Han, and R. Yang, "Angiogenesis and antiangiogenic therapy in hematologic malignancies, " Critical Reviews in Oncology/Hematology, vol. 62, no. 2, pp. 105-118, 2007. (Pubitemid 46584811)
114. W. W. Li, M. Hutnik, and G. Gehr, "Antiangiogenesis in haematological malignancies, " British Journal of Haematology, vol. 143, no. 5, pp. 622-631, 2008.
115. A. T. Stopeck, J. M. Unger, L. M. Rimsza, et al., "A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108, " Leukemia and Lymphoma, vol. 50, no. 5, pp. 728-735, 2009.
116. D. Ribatti, "Lymphangiogenesis in haematological malignancies, " Leukemia Research, vol. 33, no. 6, pp. 753-755, 2009.
117. D. Ribatti, "Is angiogenesis essential for the progression of hematological malignancies or is it an epiphenomenon?" Leukemia, vol. 23, no. 3, pp. 433-434, 2009.
118. S. V. Rajkumar, R. A. Mesa, and A. Tefferi, "A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies, " Journal of Hematotherapy and Stem Cell Research, vol. 11, no. 1, pp. 33-47, 2002. (Pubitemid 34163769)
119. T. Kessler, F. Fehrmann, R. Bieker, W. E. Berdel, and R. M. Mesters, "Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies, " Current Drug Targets, vol. 8, no. 2, pp. 257-268, 2007.
120. D. Ribatti, B. Nico, E. Crivellato, A. M. Roccaro, and A. Vacca, "The history of the angiogenic switch concept, " Leukemia, vol. 21, no. 1, pp. 44-52, 2007. (Pubitemid 44921833)
121. M. S. O'Reilly, T. Boehm, Y. Shing, et al., "Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, " Cell, vol. 88, no. 2, pp. 277-285, 1997. (Pubitemid 28015876)
122. M. S. O'Reilly, L. Holmgren, Y. Shing, et al., "Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth, " Cold Spring Harbor Symposia on Quantitative Biology, vol. 59, pp. 471-482, 1994.
123. K. Gupta, P. Gupta, R. Wild, S. Ramakrishnan, and R. P. Hebbel, "Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis, " Angiogenesis, vol. 3, no. 2, pp. 147-158, 1999. (Pubitemid 129644641)
124. P. Nyberg, L. Xie, and R. Kalluri, "Endogenous inhibitors of angiogenesis, " Cancer Research, vol. 65, no. 10, pp. 3967-3979, 2005. (Pubitemid 40775631)
125. F. Haviv, M. F. Bradley, D. M. Kalvin, et al., "Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities, " Journal ofMedicinal Chemistry, vol. 48, no. 8, pp. 2838-2846, 2005. (Pubitemid 40548098)
126. R. Hoekstra, F. Y. F. L. De Vos, F. A. L.M. Eskens, et al., "Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1- mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer, " Journal of Clinical Oncology, vol. 23, no. 22, pp. 5188-5197, 2005. (Pubitemid 46224028)
127. A. Tomillero and M. A. Moral, "Gateways to clinical trials, " Methods and Findings in Experimental and Clinical Pharmacology, vol. 30, no. 5, pp. 383-408, 2008.
128. S. N. Markovic, V. J. Suman, R. A. Rao, et al., "A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma, " American Journal of Clinical Oncology, vol. 30, no. 3, pp. 303-309, 2007. (Pubitemid 46884153)
129. S. Ebbinghaus, M. Hussain, N. Tannir, et al., "Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma, " Clinical Cancer Research, vol. 13, no. 22, pp. 6689-6695, 2007. (Pubitemid 350206805)
130. R. A. Brekken, J. P. Overholser, V. A. Stastny, J. Waltenberger, J. D. Minna, and P. E. Thorpe, "Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice, " Cancer Research, vol. 60, no. 18, pp. 5117-5124, 2000.
131. L. Witte, D. J. Hicklin, Z. Zhu, et al., "Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy, " Cancer and Metastasis Reviews, vol. 17, no. 2, pp. 155-161, 1998. (Pubitemid 28391949)
132. S. Shinkaruk, M. Bayle, G. Lain, and G. Deleris, "Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy, " Current Medicinal Chemistry, vol. 3, no. 2, pp. 95-117, 2003. (Pubitemid 36221732)
133. G. Ranieri, R. Patruno, E. Ruggieri, S. Montemurro, P. Valerio, and D. Ribatti, "Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic, " Current Medicinal Chemistry, vol. 13, no. 16, pp. 1845-1857, 2006.
134. S. Lien and H. B. Lowman, "Therapeutic anti-VEGF antibodies, " Handbook of Experimental Pharmacology, no. 181, pp. 131-150, 2008.
135. M. R. Barakat and P. K. Kaiser, "VEGF inhibitors for the treatment of neovascular age-related macular degeneration, " Expert Opinion on Investigational Drugs, vol. 18, no. 5, pp. 637-646, 2009.
136. T. A. Ciulla and P. J. Rosenfeld, "Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration, " Current Opinion in Ophthalmology, vol. 20, no. 3, pp. 166-174, 2009.
137. A. R. Quesada, M. A. Medina, and E. Alba, "Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer, " BioEssays, vol. 29, no. 11, pp. 1159-1168, 2007. (Pubitemid 350057387)
138. L. Ellis and D. J. Hicklin, "Pathways mediating resistance to vascular endothelial growth factor-targeted therapy, " Clinical Cancer Research, vol. 14, no. 20, pp. 6371-6375, 2008.
139. S. Loges, M. Mazzone, P. Hohensinner, and P. Carmeliet, "Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited, " Cancer Cell, vol. 15, no. 3, pp. 167-170, 2009.
140. M. Paez-Ribes, E. Allen, J. Hudock, et al., "Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, " Cancer Cell, vol. 15, no. 3, pp. 220-231, 2009.
141. J. M. L. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, and R. S. Kerbel, "Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis, " Cancer Cell, vol. 15, no. 3, pp. 232-239, 2009.
142. J. Ma and D. J. Waxman, "Combination of antiangiogenesis with chemotherapy for more effective cancer treatment, " Molecular Cancer Therapeutics, vol. 7, no. 12, pp. 3670-3684, 2008.
143. A. C. Dudley and M. Klagsbrun, "Tumor endothelial cells join the resistance, " Clinical Cancer Research, vol. 15, no. 15, pp. 4787-4789, 2009.
144. D. Wei, X. Le, L. Zheng, et al., "Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer
145. G. L. Semenza, "HIF-1 and tumor progression: pathophysiology and therapeutics, " Trends inMolecularMedicine, vol. 8, no. 4, pp. S62-S67, 2002. (Pubitemid 34297081)
146. Q. Ke and M. Costa, "Hypoxia-inducible factor-1 (HIF-1), " Molecular Pharmacology, vol. 70, no. 5, pp. 1469-1480, 2006.
147. G. L. Semenza, "HIF-1 and mechanisms of hypoxia sensing, " Current Opinion in Cell Biology, vol. 13, no. 2, pp. 167-171, 2001. (Pubitemid 32209217)
148. I. P. Stolze, D. R. Mole, and P. J. Ratcliffe, "Regulation of HIF: prolyl hydroxylases, " Novartis Foundation Symposium, vol. 272, pp. 15-25, 2006.
149. H. Baumann and J. Gauldie, "The acute phase response, " Immunology Today, vol. 15, no. 2, pp. 74-80, 1994. (Pubitemid 24049800)
150. N. Ohbayashi, O. Ikeda, N. Taira, et al., "LIF-and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation, " Biological and Pharmaceutical Bulletin, vol. 30, no. 10, pp. 1860-1864, 2007. (Pubitemid 47607769)
151. Q. Xu, J. Briggs, S. Park, et al., "Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways, " Oncogene, vol. 24, no. 36, pp. 5552-5560, 2005. (Pubitemid 43119350)
152. P. Yue and J. Turkson, "Targeting STAT3 in cancer: how successful are we?" Expert Opinion on Investigational Drugs, vol. 18, no. 1, pp. 45-56, 2009.
153. D. R. Hodge, E. M. Hurt, and W. L. Farrar, "The role of IL-6 and STAT3 in inflammation and cancer, " European Journal of Cancer, vol. 41, no. 16, pp. 2502-2512, 2005. (Pubitemid 41540626)
154. W. E. Naugler and M. Karin, "NF-κB and cancer-identifying targets and mechanisms, " Current Opinion in Genetics and Development, vol. 18, no. 1, pp. 19-26, 2008.
155. A. Keutgens, I. Robert, P. Viatour, and A. Chariot, "Deregulated NF-κB activity in haematological malignancies, " Biochemical Pharmacology, vol. 72, no. 9, pp. 1069-1080, 2006. (Pubitemid 44479739)
156. T. Braun, G. Carvalho, C. Fabre, J. Grosjean, P. Fenaux, and G. Kroemer, "Targeting NF-κB in hematologicmalignancies, " Cell Death and Differentiation, vol. 13, no. 5, pp. 748-758, 2006.
157. B. B. Aggarwal, "Nuclear factor-κB: the enemy within, " Cancer Cell, vol. 6, no. 3, pp. 203-208, 2004.
158. S. Ghisletti, W. Huang, S. Ogawa, et al., "Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRs and PPARγ, " Molecular Cell, vol. 25, no. 1, pp. 57-70, 2007. (Pubitemid 46049061)
159. J.-H. Yi, S.-W. Park, R. Kapadia, and R. Vemuganti, "Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage, " Neurochemistry International, vol. 50, no. 7-8, pp. 1014-1027, 2007. (Pubitemid 46962819)
160. K. Subbaramaiah, D. T. Lin, J. C. Hart, and A. J. Dannenberg, "Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREBbinding protein/p300, " Journal of Biological Chemistry, vol. 276, no. 15, pp. 12440-12448, 2001.
161. I. Kuzu, M. Beksac, M. Arat, H. Celebi, A. H. Elhan, and S. Erekul, "Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival, " Leukemia and Lymphoma, vol. 45, no. 6, pp. 1185-1190, 2004. (Pubitemid 38584901)
162. K. Anargyrou, M.-A. Dimopoulos, O. Sezer, and E. Terpos, "Novel anti-myeloma agents and angiogenesis, " Leukemia and Lymphoma, vol. 49, no. 4, pp. 677-689, 2008. (Pubitemid 351517212)
163. K. C. Anderson, "Multiple Myeloma. Advances in disease biology: therapeutic implications, " Seminars in Hematology, vol. 38, no. 2, supplement 3, pp. 6-10, 2001. (Pubitemid 32319306)
164. K. C. Anderson, "Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions, " Experimental Hematology, vol. 35, no. 4, supplement 1, pp. 155-162, 2007. (Pubitemid 46427993)
165. M. T. Cibeira, M. Rozman, M. Segarra, et al., "Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents, " Cytokine, vol. 41, no. 3, pp. 244-253, 2008.
166. M. A. Dimopoulos and E. Kastritis, "Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma, " Nature Clinical Practice Oncology, vol. 5, no. 12, pp. 690-691, 2008.
167. J. Folkman and M. S. Rogers, "Thalidomide for multiple myeloma, " The New England Journal of Medicine, vol. 354, no. 22, pp. 2389-2390, 2006.
168. A. Vacca, C. Scavelli, V. Montefusco, et al., "Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma, " Journal of Clinical Oncology, vol. 23, no. 23, pp. 5334-5346, 2005. (Pubitemid 46206987)
169. D. Mangieri, B. Nico, V. Benagiano, M. De Giorgis, A. Vacca, and D. Ribatti, "Angiogenic activity of multiple myeloma endothelial cells in vivo in the chick embryo chorioallantoic membrane assay is associated to a down-regulation in the expression of endogenous endostatin, " Journal of Cellular and Molecular Medicine, vol. 12, no. 3, pp. 1023-1028, 2008. (Pubitemid 351718079)
170. T. Letilovic, R. Vrhovac, S. Verstovsek, B. Jaksic, and A. Ferrajoli, "Role of angiogenesis in chronic lymphocytic leukemia, " Cancer, vol. 107, no. 5, pp. 925-934, 2006. (Pubitemid 44291140)
171. P. Liu, J. Li, Z. C. Han, et al., "Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia, " Leukemia and Lymphoma, vol. 46, no. 12, pp. 1761-1764, 2005. (Pubitemid 43203111)
172. E. S. Wang, J. Teruya-Feldstein, Y. Wu, Z. Zhu, D. J. Hicklin, and M. A. S. Moore, "Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo, " Blood, vol. 104, no. 9, pp. 2893-2902, 2004. (Pubitemid 39434977)
173. J. Ruan and J. P. Leonard, "Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma, " Leukemia and Lymphoma, vol. 50, no. 5, pp. 679-681, 2009.
174. T. Mainou-Fowler, B. Angus, S. Miller, S. J. Proctor, P. R. A. Taylor, and K. M. Wood, "Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL), " Leukemia and Lymphoma, vol. 47, no. 2, pp. 223-230, 2006. (Pubitemid 43084560)
175. A. Rueda, D. Olmos, V. Villareal, E. Torres, B. I. Pajares, and E. Alba, "Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission, " Clinical Lymphoma and Myeloma, vol. 7, no. 6, pp. 400-405, 2007. (Pubitemid 47057018)
176. G. Lenz, G. Wright, S. S. Dave, et al., "Stromal gene signatures in large-B-cell lymphomas, " The New England Journal of Medicine, vol. 359, no. 22, pp. 2313-2323, 2008.
177. A. Tzankov, S. Heiss, S. Ebner, et al., "Angiogenesis in nodal B cell lymphomas: a high throughput study, " Journal of Clinical Pathology, vol. 60, no. 5, pp. 476-482, 2007. (Pubitemid 46867154)
178. K. J. Till, D. G. Spiller, R. J. Harris, H. Chen, M. Zuzel, and J. C. Cawley, "CLL, but not normal, B cells are dependent on autocrine VEGF and α4β1 integrin for chemokine-induced motility on and through endothelium, " Blood, vol. 105, no. 12, pp. 4813-4819, 2005. (Pubitemid 40807308)
179. T. Matsumoto, T. Kobayashi, and K. Kamata, "Relationships among ET-1, PPARγ, oxidative stress and endothelial dysfunction in diabetic animals, " Journal of Smooth Muscle Research, vol. 44, no. 2, pp. 41-55, 2008.
180. U. Landmesser, B. Hornig, and H. Drexler, "Endothelial function: a critical determinant in atherosclerosis?" Circulation, vol. 109, no. 21, supplement 1, pp. II27-II33, 2004. (Pubitemid 38724153)
181. C. Hafner, A. Reichle, and T. Vogt, "New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy, " Current Cancer Drug Targets, vol. 5, no. 6, pp. 393-419, 2005. (Pubitemid 41176178)
182. L. Michalik and W. Wahli, "PPARs mediate lipid signaling in inflammation and cancer, " PPAR Research, vol. 2008, Article ID 134059, 15 pages, 2008.
183. L. Gelman, J.-C. Fruchart, and J. Auwerx, "An update on the mechanisms of action of the peroxisome proliferatoractivated receptors (PPARs) and their roles in inflammation and cancer, " Cellular and Molecular Life Sciences, vol. 55, no. 6-7, pp. 932-943, 1999. (Pubitemid 29304447)
184. F. Biscetti, G. Straface, D. Pitocco, F. Zaccardi, G. Ghirlanda, and A. Flex, "Peroxisome proliferator-activated receptors and angiogenesis, " Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 11, pp. 751-759, 2009.
185. A. Papi, P. Rochhi, A. M. Ferreri, F. Guerra, and M. Orlandi, "Enhanced effects of PPARγ ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells, " Oncology Reports, vol. 21, no. 4, pp. 1083-1089, 2009.
186. X. Y. Yang, L. H. Wang, and W. L. Farrar, "A role for PPARγ in the regulation of cytokines in immune cells and cancer, " PPAR Research, vol. 2008, Article ID 961753, 12 pages, 2008.
187. K. Tachibana, D. Yamasaki, K. Ishimoto, and T. Doi, "The role of PPARs in cancer, " PPAR Research, vol. 2008, Article ID 102737, 15 pages, 2008.
188. I. Sainis, K. Vareli, V. Karavasilis, and E. Briasoulis, "PPARγ: the portrait of a target ally to cancer chemopreventive agents, " PPAR Research, vol. 2008, Article ID 436489, 10 pages, 2008.
189. H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, "Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study, " Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 391-397, 2003. (Pubitemid 36750946)
190. M. H. Kulke, G. D. Demetri, N. E. Sharpless, et al., "A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer, " Cancer Journal, vol. 8, no. 5, pp. 395-399, 2002.
191. M. R. Smith, J. Manola, D. S. Kaufman, et al., "Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy, " Cancer, vol. 101, no. 7, pp. 1569-1574, 2004. (Pubitemid 39318903)
192. M. R. Gralinski, P. E. Rowse, and M. A. Breider, "Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro, " Journal of Cardiovascular Pharmacology, vol. 31, no. 6, pp. 909-913, 1998. (Pubitemid 28265301)
193. N. Marx, T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky, "PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 3, pp. 546-551, 1999. (Pubitemid 29135154)
194. T. Murata, S. He, M. Hangai, et al., "Peroxisome proliferatoractivated receptor-γ ligands inhibit choroidal neovascularization, " Investigative Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2309-2317, 2000. (Pubitemid 30451008)
195. D. Panigrahy, S. Singer, L. Q. Shen, et al., "PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis, " Journal of Clinical Investigation, vol. 110, no. 7, pp. 923-932, 2002.
196. H. Huang, S. C. Campbell, D. F. Bedford, et al., "Peroxisome proliferator-activated receptor γ ligands improve the antitumor efficacy of thrombospondin peptide ABT510, "Molecular Cancer Research, vol. 2, no. 10, pp. 541-550, 2004. (Pubitemid 39403382)
197. C.-H. Wang, N. Ciliberti, S.-H. Li, et al., "Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy, " Circulation, vol. 109, no. 11, pp. 1392-1400, 2004. (Pubitemid 38387826)
198. M. A. Sarayba, L. Li, T. Tungsiripat, et al., "Inhibition of corneal neovascularization by a peroxisome proliferatoractivated receptor-γ ligand, " Experimental Eye Research, vol. 80, no. 3, pp. 435-442, 2005. (Pubitemid 40249898)
199. L. L. H. Peeters, J.-L. Vigne, K. T. Meng, D. Zhao, L. L. Waite, and R. N. Taylor, "PPARγ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis, " Angiogenesis, vol. 8, no. 4, pp. 373-379, 2006.
200. F. Pistrosch, K. Herbrig, U. Oelschlaegel, et al., "PPARγ- agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells, " Atherosclerosis, vol. 183, no. 1, pp. 163-167, 2005. (Pubitemid 41416835)
201. C. Gensch, Y. P. Clever, C. Werner, M. Hanhoun, M. Bohm, and U. Laufs, "The PPAR-γ agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells, " Atherosclerosis, vol. 192, no. 1, pp. 67-74, 2007. (Pubitemid 46628806)
202. Q. He, R. Pang, X. Song, et al., "Rosiglitazone suppresses the growth and invasiveness of SGC-7901 gastric cancer cells and angiogenesis in vitro via PPARγ dependent and independent mechanisms, " PPAR Research, vol. 2008, Article ID 649808, 9 pages, 2008.
203. O. Gealekman, A. Burkart, M. Chouinard, S. M. Nicoloro, J. Straubhaar, and S. Corvera, "Enhanced angiogenesis in obesity and in response to PPARγ activators through adipocyte VEGF and ANGPTL4 production, " American Journal of Physiology, vol. 295, no. 5, pp. E1056-E1064, 2008.
204. L. Patel, I. Pass, P. Coxon, C. P. Downes, S. A. Smith, and C. H. Macphee, "Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN, " Current Biology, vol. 11, no. 10, pp. 764-768, 2001. (Pubitemid 32442793)
205. B. Dankbar, T. Padró, R. Leo, et al., "Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma, " Blood, vol. 95, no. 8, pp. 2630-2636, 2000. (Pubitemid 30210543)
206. T. M. Garcia-Bates, S. A. Peslak, C. J. Baglole, S. B. Maggirwar, S. H. Bernstein, and R. P. Phipps, "Peroxisome proliferatoractivated receptor gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and survival, " Cancer Immunology, Immunotherapy, vol. 58, no. 7, pp. 1071-1083, 2009.
207. T. M. Garcia-Bates, S. H. Bernstein, and R. P. Phipps, "Peroxisome proliferator-activated receptor γ overexpression suppresses growth and induces apoptosis in human multiple myeloma cells, " Clinical Cancer Research, vol. 14, no. 20, pp. 6414-6425, 2008.
208. D. M. Ray, S. H. Bernstein, and R. P. Phipps, "Human multiple myeloma cells express peroxisome proliferatoractivated receptor γ and undergo apoptosis upon exposure to PPARγ ligands, " Clinical Immunology, vol. 113, no. 2, pp. 203-213, 2004. (Pubitemid 39296854)
209. J. Padilla, E. Leung, and R. P. Phipps, "Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists, " Clinical Immunology, vol. 103, no. 1, pp. 22-33, 2002. (Pubitemid 34478417)
210. J. Padilla, K. Kaur, H. J. Cao, T. J. Smith, and R. P. Phipps, "Peroxisome proliferator activator receptor-γ agonists and 15-deoxy-δ12, 14-PGJ2 induce apoptosis in normal and malignant B-lineage cells, " Journal of Immunology, vol. 165, no. 12, pp. 6941-6948, 2000. (Pubitemid 32001165)
211. L. H. Wang, X. Y. Yang, X. Zhang, et al., "Transcriptional inactivation of STAT3 by PPARγ suppresses IL-6-responsive multiple myeloma cells, " Immunity, vol. 20, no. 2, pp. 205-218, 2004. (Pubitemid 38258396)
212. H. W. Li, Y. Y. Xiao, X. Zhang, and W. L. Farrar, "Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross talk with NF-κB and C/EBPβ, " Blood, vol. 110, no. 13, pp. 4373-4384, 2007. (Pubitemid 351377804)
213. H. W. Li, Y. Y. Xiao, X. Zhang, and W. L. Farrar, "Nuclear receptors as negative modulators of STAT3 in multiple myeloma, " Cell Cycle, vol. 4, no. 2, pp. 242-245, 2005. (Pubitemid 41365326)
214. M. Konopleva, T. Tsao, P. Ruvolo, et al., "Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia, " Blood, vol. 99, no. 1, pp. 326-335, 2002.
215. X. Ling, M. Konopleva, Z. Zeng, et al., "The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling, " Cancer Research, vol. 67, no. 9, pp. 4210-4218, 2007. (Pubitemid 46815067)
216. M. P. Curran and K. McKeage, "Bortezomib: a review of its use in patients with multiple myeloma, " Drugs, vol. 69, no. 7, pp. 859-888, 2009.
217. A. M. Roccaro, T. Hideshima, N. Raje, et al., "Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells, " Cancer Research, vol. 66, no. 1, pp. 184-191, 2006. (Pubitemid 43166024)
218. T. Hideshima, D. Chauhan, T. Hayashi, et al., "Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma, " Oncogene, vol. 22, no. 52, pp. 8386-8393, 2003. (Pubitemid 37523890)
219. S. Giralt, E. A. Stadtmauer, J. L. Harousseau, et al., "International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100), " Leukemia, vol. 23, no. 10, pp. 1904-1912, 2009.
220. M. Chatterjee, T. Stühmer, P. Herrmann, K. Bommert, B. Dörken, and R. C. Bargou, "Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells, " Blood, vol. 104, no. 12, pp. 3712-3721, 2004. (Pubitemid 39564449)
221. R. J. Epstein, "VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic, " Cancer andMetastasis Reviews, vol. 26, no. 3-4, pp. 443-452, 2007. (Pubitemid 350115101)
222. C. R. Anderson, N. E. Hastings, B. R. Blackman, and R. J. Price, "Capillary sprout endothelial cells exhibit a CD36low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating antiproliferative thrombospondin-1 signaling, " American Journal of Pathology, vol. 173, no. 4, pp. 1220-1228, 2008.
223. M. L. Febbraio, E. Guy, C. Coburn, et al., "The impact of overexpression and deficiency of fatty acid translocase (FAT)/CD36, " Molecular and Cellular Biochemistry, vol. 239, no. 1-2, pp. 193-197, 2002. (Pubitemid 35385809)
224. O. Sato, C. Kuriki, Y. Fukui, and K. Motojima, "Dual promoter structure of mouse and human fatty acid translocase/ CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor α and γ ligands, " Journal of Biological Chemistry, vol. 277, no. 18, pp. 15703-15711, 2002. (Pubitemid 34967844)
225. K. Motojima, P. Passilly, J. M. Peters, F. J. Gonzalez, and N. Latruffe, "Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue-and inducer-specific manner, " Journal of Biological Chemistry, vol. 273, no. 27, pp. 16710-16714, 1998. (Pubitemid 28311694)
226. N. Ruiz-Velasco, A. Domínguez, and M. A. Vega, "Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-γ ligands putative contribution of Rho GTPases in statin-induced CD36 expression, " Biochemical Pharmacology, vol. 67, no. 2, pp. 303-313, 2004. (Pubitemid 38112761)
227. R. Simantov and R. L. Silverstein, "CD36: a critical antiangiogenic receptor, " Frontiers in Bioscience, vol. 8, pp. s874-s882, 2003.
228. R. A. Swerlick, K. H. Lee, T. M. Wick, and T. J. Lawley, "Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro, " Journal of Immunology, vol. 148, no. 1, pp. 78-83, 1992.
229. F. K. Reiher, O. V. Volpert, B. Jimenez, et al., "Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics, " International Journal of Cancer, vol. 98, no. 5, pp. 682-689, 2002. (Pubitemid 34225618)
230. J. Liu, H. Lu, R. Huang, et al., "Peroxisome proliferator activated receptor-γ ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells, " Cancer Chemotherapy and Pharmacology, vol. 56, no. 4, pp. 400-408, 2005. (Pubitemid 41095403)
231. P. J. Simpson-Haidaris and B. Rybarczyk, "Tumors and fibrinogen: the role of fibrinogen as an extracellular matrix protein, " Annals of the New York Academy of Sciences, vol. 936, pp. 406-425, 2001. (Pubitemid 32613924)
232. P. S. Meltzer, "Cancer genomics: small RNAs with big impacts, " Nature, vol. 435, no. 7043, pp. 745-746, 2005. (Pubitemid 40839710)
233. C. H. Lawrie, "MicroRNAs and haematology: small molecules, big function, " British Journal of Haematology, vol. 137, no. 6, pp. 503-512, 2007. (Pubitemid 46817340)
234. D. P. Bartel, "MicroRNAs: target recognition and regulatory functions, " Cell, vol. 136, no. 2, pp. 215-233, 2009.
235. J. Brennecke, A. Stark, R. B. Russell, and S. M. Cohen, "Principles of microRNA-target recognition, " PLoS Biology, vol. 3, no. 3, article e85, 2005.
236. V. N. Kim, J. Han, and M. C. Siomi, "Biogenesis of small RNAs in animals, " Nature ReviewsMolecular Cell Biology, vol. 10, no. 2, pp. 126-139, 2009.
237. C. Urbich, A. Kuehbacher, and S. Dimmeler, "Role of microRNAs in vascular diseases, inflammation, and angiogenesis, " Cardiovascular Research, vol. 79, no. 4, pp. 581-588, 2008.
238. P. K. Mishra, N. Tyagi, M. Kumar, and S. C. Tyagi, "MicroRNAs as a therapeutic target for cardiovascular diseases, " Journal of Cellular and Molecular Medicine, vol. 13, no. 4, pp. 778-789, 2009.
239. A. Marson, S. S. Levine, M. F. Cole, et al., "Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells, " Cell, vol. 134, no. 3, pp. 521-533, 2008.
240. J. G. Ruby, C. H. Jan, and D. P. Bartel, "Intronic microRNA precursors that bypass Drosha processing, " Nature, vol. 448, no. 7149, pp. 83-86, 2007. (Pubitemid 47037009)
241. Y. Lee, C. Ahn, J. Han, et al., "The nuclear RNase III Drosha initiates microRNA processing, " Nature, vol. 425, no. 6956, pp. 415-419, 2003. (Pubitemid 37187272)
242. E. Lund, S. Güttinger, A. Calado, J. E. Dahlberg, and U. Kutay, "Nuclear export of microRNA precursors, " Science, vol. 303, no. 5654, pp. 95-98, 2004. (Pubitemid 38055779)
243. G. Hutvágner and P. D. Zamore, "A microRNA in a multipleturnover RNAi enzyme complex, " Science, vol. 297, no. 5589, pp. 2056-2060, 2002.
244. G. Meister, M. Landthaler, A. Patkaniowska, Y. Dorsett, G. Teng, and T. Tuschl, "Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs, " Molecular Cell, vol. 15, no. 2, pp. 185-197, 2004. (Pubitemid 38950966)
245. W. Filipowicz, S. N. Bhattacharyya, and N. Sonenberg, "Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?" Nature Reviews Genetics, vol. 9, no. 2, pp. 102-114, 2008.
246. F. Pichiorri, S.-S. Suh, M. Ladetto, et al., "MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 12885-12890, 2008.
247. M. Fabbri, C. Croce, and G. Calin, "MicroRNAs in the ontogeny of leukemias and lymphomas, " Leukemia and Lymphoma, vol. 50, no. 2, pp. 160-170, 2009.
248. G. A. Calin, C. D. Dumitru, M. Shimizu, et al., "Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15524-15529, 2002. (Pubitemid 35403967)
249. A. M. Roccaro, A. Sacco, B. Thompson, et al., "MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma, " Blood, vol. 113, no. 26, pp. 6669-6680, 2009.
250. R. Fonseca, E. Blood, M. Rue, et al., "Clinical and biologic implications of recurrent genomic aberrations in myeloma, " Blood, vol. 101, no. 11, pp. 4569-4575, 2003. (Pubitemid 36857829)
251. L. He, J. M. Thomson, M. T. Hemann, et al., "A microRNA polycistron as a potential human oncogene, " Nature, vol. 435, no. 7043, pp. 828-833, 2005. (Pubitemid 40839734)
252. Z. Li, J. Lu, M. Sun, et al., "Distinct microRNA expression profiles in acute myeloid leukemia with common translocations, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 40, pp. 15535-15540, 2008.
253. Z. Li, R. T. Luo, S. Mi, et al., "Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias, " Cancer Research, vol. 69, no. 3, pp. 1109-1116, 2009.
254. Y. Hayashita, H. Osada, Y. Tatematsu, et al., "A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation, " Cancer Research, vol. 65, no. 21, pp. 9628-9632, 2005. (Pubitemid 41541436)
255. S. Takakura, N. Mitsutake, M. Nakashima, et al., "Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells, " Cancer Science, vol. 99, no. 6, pp. 1147-1154, 2008. (Pubitemid 351676626)
256. E. Connolly, M. Melegari, P. Landgraf, et al., "Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype, " American Journal of Pathology, vol. 173, no. 3, pp. 856-864, 2008.
257. D. Löffler, K. Brocke-Heidrich, G. Pfeifer, et al., "Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer, " Blood, vol. 110, no. 4, pp. 1330-1333, 2007. (Pubitemid 47281433)
258. T. Papagiannakopoulos, A. Shapiro, and K. S. Kosik, "MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells, " Cancer Research, vol. 68, no. 19, pp. 8164-8172, 2008.
259. S. Zhu, H. Wu, F. Wu, D. Nie, S. Sheng, and Y.-Y. Mo, "MicroRNA-21 targets tumor suppressor genes in invasion and metastasis, " Cell Research, vol. 18, no. 3, pp. 350-359, 2008. (Pubitemid 351333899)
260. W. Zhang, J. E. Dahlberg, and W. Tam, "MicroRNAs in tumorigenesis: a primer, " American Journal of Pathology, vol. 171, no. 3, pp. 728-738, 2007. (Pubitemid 47440972)
261. A. Kuehbacher, C. Urbich, and S. Dimmeler, "Targeting microRNA expression to regulate angiogenesis, " Trends in Pharmacological Sciences, vol. 29, no. 1, pp. 12-15, 2008.
262. I. A. Asangani, S. A. K. Rasheed, D. A. Nikolova, et al., "MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer, " Oncogene, vol. 27, no. 15, pp. 2128-2136, 2008. (Pubitemid 351485639)
263. R. Baffa, M. Fassan, S. Volinia, et al., "MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets, " Journal of Pathology, vol. 219, no. 2, pp. 214-221, 2009.
264. L.-X. Yan, X.-F. Huang, Q. Shao, et al., "MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis, " RNA, vol. 14, no. 11, pp. 2348-2360, 2008.
265. Y. Suárez, C. Fernández-Hernando, J. S. Pober, and W. C. Sessa, "Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells, " Circulation Research, vol. 100, no. 8, pp. 1164-1173, 2007. (Pubitemid 46684129)
266. Y. Suárez, C. Fernández-Hernando, J. Yu, et al., "Dicerdependent endothelial microRNAs are necessary for postnatal angiogenesis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 37, pp. 14082-14087, 2008.
267. Y. Chen and D. H. Gorski, "Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5, " Blood, vol. 111, no. 3, pp. 1217-1226, 2008. (Pubitemid 351213403)
268. H. K. Saini, S. Griffiths-Jones, and A. J. Enright, "Genomic analysis of human microRNA transcripts, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 45, pp. 17719-17724, 2007. (Pubitemid 350210901)
269. T. Avnit-Sagi, L. Kantorovich, S. Kredo-Russo, E. Hornstein, and M. D. Walker, "The promoter of the pri-miR-375 gene directs expression selectively to the endocrine pancreas, " PLoS ONE, vol. 4, no. 4, article e5033, 2009.
270. C. H. Lawrie, C. D. O. Cooper, E. Ballabio, J. Chi, D. Tramonti, and C. S. R. Hatton, "Aberrant expression of microRNA biosynthetic pathway components is a common feature of haematological malignancy, " British Journal of Haematology, vol. 145, no. 4, pp. 545-548, 2009.
271. D. Iliopoulos, H. A. Hirsch, and K. Struhl, "An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation, " Cell, vol. 139, no. 4, pp. 693-706, 2009.
272. V. B. Sampson, N. H. Rong, J. Han, et al., "MicroRNA let-7a down-regulates MYC and revertsMYC-induced growth in Burkitt lymphoma cells, " Cancer Research, vol. 67, no. 20, pp. 9762-9770, 2007. (Pubitemid 47621223)
273. A. K. Ghosh, T. D. Shanafelt, A. Cimmino, et al., "Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells, " Blood, vol. 113, no. 22, pp. 5568-5574, 2009.
274. Q. Lin, Z. Gao, R. M. Alarcon, J. Ye, and Z. Yun, "A role of miR-27 in the regulation of adipogenesis, " FEBS Journal, vol. 276, no. 8, pp. 2348-2358, 2009.
275. A. C. Morrill and C. D. Chinn, "The obesity epidemic in the United States, " Journal of Public Health Policy, vol. 25, no. 3-4, pp. 353-366, 2004. (Pubitemid 40021759)
276. E. E. Calle, C. Rodriguez, K. Walker-Thurmond, and M. J. Thun, "Overweight, obesity, and mortality from cancer in a prospectively studied cohort ofU.S. adults, " TheNew England Journal of Medicine, vol. 348, no. 17, pp. 1625-1638, 2003. (Pubitemid 36459468)
277. S. C. Larsson and A. Wolk, "Body mass index and risk of multiple myeloma: a meta-analysis, " International Journal of Cancer, vol. 121, no. 11, pp. 2512-2516, 2007. (Pubitemid 350022422)
278. C. K. Blair, J. R. Cerhan, A. R. Folsom, and J. A. Ross, "Anthropometric characteristics and risk of multiple myeloma, " Epidemiology, vol. 16, no. 5, pp. 691-694, 2005. (Pubitemid 41233625)
279. C. Bosetti, E. Negri, S. Gallus, L. Dal Maso, S. Franceschi, and C. La Vecchia, "Anthropometry and multiple myeloma, " Epidemiology, vol. 17, no. 3, pp. 340-341, 2006.
280. K. Eder, N. Baffy, A. Falus, and A. K. Fulop, "The major inflammatory mediator interleukin-6 and obesity, " Inflammation Research, vol. 58, no. 11, pp. 727-736, 2009.
281. M. Karbiener, C. Fischer, S. Nowitsch, et al., "MicroRNA miR-27b impairs human adipocyte differentiation and targets PPARγ, " Biochemical and Biophysical Research Communications, vol. 390, no. 2, pp. 247-251, 2009.
282. J. Ji, J. Zhang, G. Huang, J. Qian, X. Wang, and S. Mei, "Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation, " FEBS Letters, vol. 583, no. 4, pp. 759-766, 2009.
283. S. Chintharlapalli, S. Papineni, M. Abdelrahim, et al., "Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3, 11-dioxo-18β-olean-1, 12-dien-30-oate in colon cancer cells, " International Journal of Cancer, vol. 125, no. 8, pp. 1965-1974, 2009.
284. B. P. Lewis, I.-H. Shih, M.W. Jones-Rhoades, D. P. Bartel, and C. B. Burge, "Prediction of mammalian microRNA target, " Cell, vol. 115, no. 7, pp. 787-798, 2003.
285. B. John, A. J. Enright, A. Aravin, T. Tuschl, C. Sander, and D. S. Marks, "Human microRNA targets, " PLoS Biology, vol. 2, no. 11, article e363, 2004.
286. A. Krek, D. Grun, M. N. Poy, et al., "Combinatorial microRNA target predictions, " Nature Genetics, vol. 37, no. 5, pp. 495-500, 2005. (Pubitemid 40617277)
287. J. Kim, Y.-S. Oh, and S.-H. Shinn, "Troglitazone reverses the inhibition of nitric oxide production by high glucose in cultured bovine retinal pericytes, " Experimental Eye Research, vol. 81, no. 1, pp. 65-70, 2005. (Pubitemid 40840547)
288. C. Freeman, J. W. Berg, and S. J. Cutler, "Occurrence and prognosis
289. L. D. Ormerod and J. E. Puklin, "AIDS-associated intraocular lymphoma causing primary retinal vasculitis, " Ocular Immunology and Inflammation, vol. 5, no. 4, pp. 271-278, 1997. (Pubitemid 28043357)
290. R. H. Sagerman, W. Alberti, and D. H. Abramson, Radiotherapy of Intraocular and Orbital Tumors, Springer, New York, NY, USA, 2003.
291. C.-C. Chan, "Molecular pathology of primary intraocular lymphoma, " Transactions of the American Ophthalmological Society, vol. 101, pp. 275-292, 2003. (Pubitemid 38209334)
292. L. D. Sjö, "Ophthalmic lymphoma: epidemiology and pathogenesis, " Acta Ophthalmologica, vol. 87, thesis1, pp. 1-20, 2009.
293. S. K. Kim, C.-C. Chan, and D. J. Wallace, "Management of primary intraocular lymphoma, " Current Oncology Reports, vol. 7, no. 1, pp. 74-79, 2005. (Pubitemid 40277594)
294. K. B. Gordon, H. S. Rugo, J. L. Duncan, et al., "Ocular manifestations of leukemia: leukemic infiltration versus infectious process, " Ophthalmology, vol. 108, no. 12, pp. 2293-2300, 2001. (Pubitemid 33096945)
295. S. C. Reddy, N. Jackson, and B. S. Menon, "Ocular involvement in leukemia-a study of 288 cases, " Ophthalmologica, vol. 217, no. 6, pp. 441-445, 2003. (Pubitemid 37329240)
296. A. R. Rosenthal, "Ocular manifestations of leukemia. A review, " Ophthalmology, vol. 90, no. 8, pp. 899-905, 1983. (Pubitemid 13004300)
297. T. Sharma, J. Grewal, S. Gupta, and P. I. Murray, "Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role, " Eye, vol. 18, no. 7, pp. 663-672, 2004. (Pubitemid 39117416)
298. A. E. Omoti and C. E. Omoti, "Ophthalmicmanifestations of multiple myeloma, "West African Journal of Medicine, vol. 26, no. 4, pp. 265-268, 2007.
299. J. S. Penn, G.W. McCollum, J. M. Barnett, X. Q. Werdich, K. A. Koepke, and V. S. Rajaratnam, "Angiostatic effect of penetrating ocular injury: role of pigment epithelium-derived factor, " Investigative Ophthalmology and Visual Science, vol. 47, no. 1, pp. 405-414, 2006. (Pubitemid 46780842)
300. E. Aguilar, M. I. Dorrell, D. Friedlander, et al., "Chapter 6. Ocular models of angiogenesis, " Methods in Enzymology, vol. 444, pp. 115-158, 2008.
301. P. Henkind, "Ocular neovascularization. The Krill memorial lecture, " American Journal of Ophthalmology, vol. 85, no. 3, pp. 287-301, 1978. (Pubitemid 8313827)
302. P. Lee, C. C. Wang, and A. P. Adamis, "Ocular neovascularization: an epidemiologic review, " Survey of Ophthalmology, vol. 43, no. 3, pp. 245-269, 1998. (Pubitemid 28558273)
303. B. Kim, Q. Tang, P. S. Biswas, et al., "Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis, " American Journal of Pathology, vol. 165, no. 6, pp. 2177-2185, 2004. (Pubitemid 39578394)
304. S. X. Zhang and J. X. Ma, "Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy, " Progress in Retinal and Eye Research, vol. 26, no. 1, pp. 1-37, 2007. (Pubitemid 44920203)
305. P. A. Campochiaro, "Retinal and choroidal neovascularization, " Journal of Cellular Physiology, vol. 184, no. 3, pp. 301-310, 2000. (Pubitemid 30625492)
306. H. A. Pershadsingh and D. M. Moore, "PPARγ agonists: potential as therapeutics for neovascular retinopathies, " PPAR Research, vol. 2008, Article ID 164273, 13 pages, 2008.
307. A. Tawfik, T. Sanders, K. Kahook, S. Akeel, A. Elmarakby, and M. Al-Shabrawey, "Suppression of retinal peroxisome proliferator-activated receptor gamma in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase, " Investigative Ophthalmology and Visual Science, vol. 50, no. 2, pp. 878-884, 2009.
308. S. Qin, A. P. McLaughlin, and G. W. De Vries, "Protection of RPE cells from oxidative injury by 15-deoxy-δ12, 14-prostaglandin J2 by augmenting GSH and activating MAPK, " Investigative Ophthalmology and Visual Science, vol. 47, no. 11, pp. 5098-5105, 2006. (Pubitemid 46586417)
309. F. Willermain, S. Dulku, N. S. Gonzalez, et al., "15-Deoxy-12, 14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanism, " Prostaglandins and Other LipidMediators, vol. 80, no. 3-4, pp. 136-143, 2006. (Pubitemid 44376432)
310. Y. Sassa, Y. Hata, L. P. Aiello, Y. Taniguchi, K. Kohno, and T. Ishibashi, "Bifunctional properties of peroxisome proliferator-activated receptor γ1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3, " Diabetes, vol. 53, no. 5, pp. 1222-1229, 2004. (Pubitemid 38569007)
311. T. Murata, Y. Hata, T. Ishibashi, et al., "Response of experimental retinal neovascularization to thiazolidinediones, " Archives of Ophthalmology, vol. 119, no. 5, pp. 709-717, 2001. (Pubitemid 32417377)
312. P. Aoun, J. W. Simpkins, and N. Agarwal, "Role of PPAR-γ ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells, " Investigative Ophthalmology and Visual Science, vol. 44, no. 7, pp. 2999-3004, 2003. (Pubitemid 36759765)
313. S. E. Feldon, C. W. O'Loughlin, D. M. Ray, S. Landskroner-Eiger, K. E. Seweryniak, and R. P. Phipps, "Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes, " American Journal of Pathology, vol. 169, no. 4, pp. 1183-1193, 2006. (Pubitemid 351194355)
314. D. Pasquali, G. M. Pierantoni, A. Fusco, et al., "Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy, " Journal of Molecular Endocrinology, vol. 33, no. 1, pp. 133-143, 2004. (Pubitemid 39206353)
315. H.-C. Cheng, T.-C. Ho, S.-L. Chen, H.-Y. Lai, K.-F. Hong, and Y.-P. Tsao, "Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells, " Molecular Vision, vol. 14, pp. 95-104, 2008. (Pubitemid 351167709)
316. M. Artwohl, C. Furnsinn, W. Waldhausl, et al., "Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARγ-independent mechanism, " Diabetologia, vol. 48, no. 3, pp. 586-594, 2005. (Pubitemid 40487307)
317. L. Q. Shen, A. Child, G. M. Weber, J. Folkman, and L. P. Aiello, "Rosiglitazone and delayed onset of proliferative diabetic retinopathy, " Archives of Ophthalmology, vol. 126, no. 6, pp. 793-799, 2008. (Pubitemid 351831328)
318. M. A. K. Rumi, S. Ishihara, H. Kazumori, Y. Kadowaki, and Y. Kinoshita, "Can PRARγ ligands be used in cancer therapy?" CurrentMedicinal Chemistry, vol. 4, no. 6, pp. 465-477, 2004. (Pubitemid 39406260)
319. E. Papageorgiou, N. Pitulis, P. Msaouel, P. Lembessis, and M. Koutsilieris, "The non-genomic crosstalk between PPAR-γ ligands and ERK1/2 in cancer cell lines, " Expert Opinion on Therapeutic Targets, vol. 11, no. 8, pp. 1071-1085, 2007. (Pubitemid 47240680)
320. D. P. Kelly, "The pleiotropic nature of the vascular PPAR gene regulatory pathway, " Circulation Research, vol. 89, no. 11, pp. 935-937, 2001. (Pubitemid 34640858)
321. A. R. Collins, "Pleiotropic vascular effects of PPARγ ligands, " Drug News and Perspectives, vol. 16, no. 4, pp. 197-204, 2003. (Pubitemid 37039400)
322. H. Takano, H.Hasegawa, Y. Zou, and I. Komuro, "Pleiotropic actions of PPARγ activators thiazolidinediones in cardiovascular diseases, " Current Pharmaceutical Design, vol. 10, no. 22, pp. 2779-2786, 2004. (Pubitemid 39137176)
323. N. L. Julie, I. M. Julie, A. I. Kende, and G. L. Wilson, "Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone, " Diabetologia, vol. 51, no. 11, pp. 2108-2116, 2008.
324. C. V. Rizos, M. S. Elisaf, D. P. Mikhailidis, and E. N. Liberopoulos, "How safe is the use of thiazolidinediones in clinical practice?" Expert Opinion on Drug Safety, vol. 8, no. 1, pp. 15-32, 2009.
325. D. H. Solomon, S. M. Cadarette, N. K. Choudhry, C. Canning, R. Levin, and T. Sturmer, "A cohort study of thiazolidinediones and fractures in older adults with diabetes, " Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 8, pp. 2792-2798, 2009.
326. R. A. Kyle and S. V. Rajkumar, "Treatment of multiple myeloma: a comprehensive review, " Clinical Lymphoma, Myeloma & Leukemia, vol. 9, no. 4, pp. 278-288, 2009.
327. M. Wang and S. Tafuri, "Modulation of PPARγ activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis, " Journal of Cellular Biochemistry, vol. 89, no. 1, pp. 38-47, 2003. (Pubitemid 36459096)
328. U. Campia, L. A. Matuskey, and J. A. Panza, "Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors, " Circulation, vol. 113, no. 6, pp. 867-875, 2006.
329. A. Pfutzner, C. Hohberg, G. Lubben, et al., "Pioneer study: PPARγ activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control, " Hormone and Metabolic Research, vol. 37, no. 8, pp. 510-515, 2005. (Pubitemid 41306402)
330. K. Yamakawa, M. Hosoi, H. Koyama, et al., "Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells, " Biochemical and Biophysical Research Communications, vol. 271, no. 3, pp. 571-574, 2000. (Pubitemid 30444669)
331. K. Chu, S.-T. Lee, J.-S. Koo, et al., "Peroxisome proliferatoractivated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia, " Brain Research, vol. 1093, no. 1, pp. 208-218, 2006. (Pubitemid 43946402)
332. S. Z. Duan, M. G. Usher, and R. M. Mortensen, "Peroxisome proliferator-activated receptor-γ-mediated effects in the vasculature, " Circulation Research, vol. 102, no. 3, pp. 283-294, 2008. (Pubitemid 351271648)
333. S. Singh, Y. K. Loke, and C. D. Furberg, "Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis, " Journal of the American Medical Association, vol. 298, no. 10, pp. 1189-1195, 2007. (Pubitemid 47403105)
334. A. Zinn, S. Felson, E. Fisher, and A. Schwartzbard, "Reassessing the cardiovascular risks and benefits of thiazolidinediones, " Clinical Cardiology, vol. 31, no. 9, pp. 397-403, 2008.
335. E. Mannucci, M. Monami, M. Di Bari, et al., "Cardiac safety profile of rosiglitazone. A comprehensive meta-analysis of randomized clinical trials, " to appear in International Journal of Cardiology.
336. D. N. Juurlink, T. Gomes, L. L. Lipscombe, P. C. Austin, J. E. Hux, and M. M. Mamdani, "Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study, " British Medical Journal, vol. 339, article b2942, 2009.
337. B. R. Bird and S. M. Swain, "Cardiac toxicity in breast cancer survivors: review of potential cardiac problems, " Clinical Cancer Research, vol. 14, no. 1, pp. 14-24, 2008. (Pubitemid 351377973)
338. K. Towns, P. L. Bedard, and S. Verma, "Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer, " Current Oncology, vol. 15, pp. S16-S29, 2008.
339. M. Sereno, A. Brunello, A. Chiappori, et al., "Cardiac toxicity: old and new issues in anti-cancer drugs, " Clinical and Translational Oncology, vol. 10, no. 1, pp. 35-46, 2008.
340. D. E. Gerber, "Targeted therapies: a new generation of cancer treatments, " American Family Physician, vol. 77, no. 3, pp. 311-319, 2008. (Pubitemid 351206593)
341. N. T. Ihle, R. Lemos, D. Schwartz, et al., "Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity, "Molecular Cancer Therapeutics, vol. 8, no. 1, pp. 94-100, 2009.
342. D. Veliceasa, F. T. Schulze-Hoepfner, and O. V. Volpert, "PPARγ and agonists against cancer: rational design of complementation treatments, " PPAR Research, vol. 2008, Article ID 945275, 13 pages, 2008.
343. M. L. G. Janssen-Heijnen, H. A. A. M. Maas, S. Houterman, V. E. P. P. Lemmens, H. J. T. Rutten, and J. W. W. Coebergh, "Comorbidity in older surgical cancer patients: influence on patient care and outcome, " European Journal of Cancer, vol. 43, no. 15, pp. 2179-2193, 2007. (Pubitemid 47539116)
344. J. Shen, X. Yang, B. Xie, et al., "MicroRNAs regulate ocular neovascularization, " Molecular Therapy, vol. 16, no. 7, pp. 1208-1216, 2008. (Pubitemid 351866051)
345. Y. M. Shah, K. Morimura, Q. Yang, T. Tanabe, M. Takagi, and F. J. Gonzalez, "Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation, " Molecular and Cellular Biology, vol. 27, no. 12, pp. 4238-4247, 2007. (Pubitemid 46906549)
346. R. S. McIntyre, J. K. Soczynska, H. O. Woldeyohannes, et al., "Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?" Expert Opinion on Pharmacotherapy, vol. 8, no. 11, pp. 1615-1628, 2007. (Pubitemid 47288172)
347. J. M. Roodhart, M. H. Langenberg, E. Witteveen, and E. E. Voest, "The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway, " Current Clinical Pharmacology, vol. 3, no. 2, pp. 132-143, 2008.
348. C. A. Krone and J. T. A. Ely, "Controlling hyperglycemia as an adjunct to cancer therapy, " Integrative Cancer Therapies, vol. 4, no. 1, pp. 25-31, 2005. (Pubitemid 40250675)
349. T. M. McIntyre, A. V. Pontsler, A. R. Silva, et al., "Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 131-136, 2003. (Pubitemid 36078041)
350. F. J. Schopfer, Y. Lin, P. R. S. Baker, et al., "Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340-2345, 2005. (Pubitemid 40279377)
351. C. Ulivieri and C. T. Baldari, "The potential of peroxisome proliferator-activated receptor γ (PPARγ) ligands in the treatment of hematological malignancies, " Mini-Reviews in Medicinal Chemistry, vol. 7, no. 9, pp. 877-887, 2007. (Pubitemid 47554778)
352. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, "The PPARs: from orphan receptors to drug discovery, " Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527-550, 2000. (Pubitemid 30127149)
353. T. Wang, J. Xu, X. Yu, R. Yang, and Z. C. Han, "Peroxisome proliferator-activated receptor γ in malignant diseases, " Critical Reviews in Oncology/Hematology, vol. 58, no. 1, pp. 1-14, 2006.
354. L. Gelman, J. N. Feige, and B. Desvergne, "Molecular basis of selective PPARγ modulation for the treatment of Type 2 diabetes, " Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1094-1107, 2007. (Pubitemid 47214561)
355. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, "15-deoxy-δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ, " Cell, vol. 83, no. 5, pp. 803-812, 1995. (Pubitemid 3006324)
356. S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, "A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation, " Cell, vol. 83, no. 5, pp. 813-819, 1995. (Pubitemid 3006325)
357. J. Wigren, S. Surapureddi, A. G. Olsson, C. K. Glass, S. Hammarstrom, and M. Soderstrom, "Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein, " Journal of Endocrinology, vol. 177, no. 2, pp. 207-214, 2003. (Pubitemid 36656393)
358. B. Staels and J.-C. Fruchart, "Therapeutic roles of peroxisome proliferator-activated receptor agonists, " Diabetes, vol. 54, no. 8, pp. 2460-2470, 2005. (Pubitemid 41134276)
359. C. Zang, H. Liu, M. Waechter, et al., "Dual PPARα/γ ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines, " Cell Cycle, vol. 5, no. 19, pp. 2237-2243, 2006. (Pubitemid 44546560)
360. M.-B. Debril, J.-P. Renaud, L. Fajas, and J. Auwerx, "The pleiotropic functions of peroxisome proliferator-activated receptor γ, " Journal of Molecular Medicine, vol. 79, no. 1, pp. 30-47, 2001. (Pubitemid 32250021)
361. K. L. Houseknecht, B. M. Cole, and P. J. Steele, "Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: a review, " Domestic Animal Endocrinology, vol. 22, no. 1, pp. 1-23, 2002. (Pubitemid 34438654)
362. C. Qin, D. Morrow, J. Stewart, et al., "A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1, 1-Bis(3′-indolyl)-1-(p-substituted phenyl) methanes, " Molecular Cancer Therapeutics, vol. 3, no. 3, pp. 247-259, 2004. (Pubitemid 39193700)
363. Y. Ito, P. Pandey, A. Place, et al., "The novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism, " Cell Growth and Differentiation, vol. 11, no. 5, pp. 261-267, 2000. (Pubitemid 30347206)
364. N. Suh, Y. Wang, T. Honda, et al., "A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity, " Cancer Research, vol. 59, no. 2, pp. 336-341, 1999.
365. R. Contractor, I. J. Samudio, Z. Estrov, et al., "A novel ring-substituted diindolylmethane, 1, 1-bis[3-(5-methoxyindolyl)]-1-(p-t- butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia, " Cancer Research, vol. 65, no. 7, pp. 2890-2898, 2005. (Pubitemid 40490093)
366. S. Fujimura, J. Suzumiya, K. Nakamura, and J. Ono, "Effects of troglitazone on the growth and differentiation of hematopoietic cell lines, " International Journal of Oncology, vol. 13, no. 6, pp. 1263-1267, 1998. (Pubitemid 28551554)
367. N. Yamakawa-Karakida, K. Sugita, T. Inukai, et al., "Ligand activation of peroxisome proliferator-activated receptor γ induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity, " Cell Death and Differentiation, vol. 9, no. 5, pp. 513-526, 2002. (Pubitemid 34521179)
368. J. J. Liu, R.W. Huang, D. J. Lin, et al., "Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-γ ligands induces apoptosis on human myeloid leukemia cells in vitro, " Annals of Oncology, vol. 16, no. 3, pp. 455-459, 2005. (Pubitemid 40458324)
369. J.-J. Liu, P.-Q. Liu, D.-J. Lin, et al., "Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-γ agonists induced apoptosis in human monocyte leukemia cells in vitro, " Annals of Hematology, vol. 86, no. 3, pp. 173-183, 2007. (Pubitemid 46195989)
370. H. Han, S.-W. Shin, C.-Y. Seo, et al., "15-Deoxy-δ12, 14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-induced apoptosis through Akt downregulation, " Apoptosis, vol. 12, no. 11, pp. 2101-2114, 2007. (Pubitemid 47498232)
371. S. Nakata, T. Yoshida, T. Shiraishi, et al., "15-Deoxy-δ12, 14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPARγ and potentiates TRAIL-induced apoptosis, " Molecular Cancer Therapeutics, vol. 5, no. 7, pp. 1827-1835, 2006. (Pubitemid 44323251)
372. A. Sugimura, Y. Kiriyama, H. Nochi, et al., "Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor, " Biochemical and Biophysical Research Communications, vol. 261, no. 3, pp. 833-837, 1999. (Pubitemid 29408143)
373. M. Konopleva, E. Elstner, T. J. McQueen, et al., "Peroxisome proliferator-activated receptor and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias, " Molecular Cancer Therapeutics, vol. 3, no. 10, pp. 1249-1262, 2004. (Pubitemid 39440170)
374. N. Hirase, T. Yanase, Y.-M. Mu, et al., "Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60, " Oncology, vol. 57, supplement 2, pp. 17-25, 1999. (Pubitemid 29494881)
375. H. Asou, W. Verbeek, E. Williamson, et al., "Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids, " International Journal of Oncology, vol. 15, no. 5, pp. 1027-1031, 1999.
376. E. Yasugi, A. Horiuchi, I. Uemura, et al., "Peroxisome proliferator-activated receptor γ ligands stimulate myeloid differentiation and lipogenensis in human leukemia NB4 cells, " Development Growth and Differentiation, vol. 48, no. 3, pp. 177-188, 2006.
377. S. Koschmieder, F. D'Alo, H. Radomska, et al., "CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer-binding protein alpha, " Blood, vol. 110, no. 10, pp. 3695-3705, 2007. (Pubitemid 350159639)
378. Y. Tabe, M. Konopleva, Y. Kondo, et al., "PPARγ-active triterpenoid CDDO enhances ATRA-induced differentiation in APL, " Cancer Biology and Therapy, vol. 6, no. 12, pp. 1967-1977, 2007. (Pubitemid 351590411)
379. M. Konopleva, T. Tsao, Z. Estrov, et al., "The synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia, " Cancer Research, vol. 64, no. 21, pp. 7927-7935, 2004. (Pubitemid 39446926)
380. T. Ikeda, M. Sporn, T. Honda, G. W. Gribble, and D. Kufe, "The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance, " Cancer Research, vol. 63, no. 17, pp. 5551-5558, 2003. (Pubitemid 37139877)
381. L. Zhu, B. Gong, C. L. Bisgaier, M. Aviram, and R. S. Newton, "Induction of PPARγ1 expression in human THP-1 monocytic leukemia cells by 9-cis-retinoic acid is associated with cellular growth suppression, " Biochemical and Biophysical Research Communications, vol. 251, no. 3, pp. 842-848, 1998. (Pubitemid 28512798)
382. U. Kintscher, S. Goetze, S. Wakino, et al., "Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes, " European Journal of Pharmacology, vol. 401, no. 3, pp. 259-270, 2000. (Pubitemid 30608710)
383. H. Liu, C. Zang, M. H. Fenner, et al., "Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18, " Blood, vol. 107, no. 9, pp. 3683-3692, 2006.
384. N. Hirase, T. Yanase, Y.-M. Mu, et al., "Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562, " Leukemia Research, vol. 24, no. 5, pp. 393-400, 2000. (Pubitemid 30227239)
385. C. Zang, H. Liu, M. G. Posch, et al., "Peroxisome proliferatoractivated receptor γ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia, " Leukemia Research, vol. 28, no. 4, pp. 387-397, 2004. (Pubitemid 38199947)
386. M. Takenokuchi, K. Saigo, Y. Nakamachi, et al., "Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18), " Acta Haematologica, vol. 116, no. 1, pp. 30-40, 2006. (Pubitemid 43990955)
387. R. Piva, P. Gianferretti, A. Ciucci, R. Taulli, G. Belardo, and M. G. Santoro, "15-Deoxy-δ12, 14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins, " Blood, vol. 105, no. 4, pp. 1750-1758, 2005. (Pubitemid 40223699)
388. S. G. Harris and R. P. Phipps, "Prostaglandin D2, its metabolite 15-d-PGJ2, and peroxisome proliferator activated receptor-γ agonists induce apoptosis in transformed, but not normal, human T lineage cells, " Immunology, vol. 105, no. 1, pp. 23-34, 2002. (Pubitemid 34128037)
389. C. Yang, S.-H. Jo, B. Csernus, et al., "Activation of peroxisome proliferator-activated receptor γ contributes to the survival of T lymphoma cells by affecting cellular metabolism, " American Journal of Pathology, vol. 170, no. 2, pp. 722-732, 2007. (Pubitemid 47339406)
390. C. Zhang, X. Ni, M. Konopleva, M. Andreeff, andM. Duvic, "The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycocis fungoides/Sezary syndrome cells, " Journal of Investigative Dermatology, vol. 123, no. 2, pp. 380-387, 2004. (Pubitemid 38951834)
391. J. Eucker, J. Sterz, H. Krebbel, et al., "Peroxisome proliferatoractivated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma, " Anti-Cancer Drugs, vol. 17, no. 7, pp. 763-769, 2006. (Pubitemid 44310173)
392. I. M. Pedersen, S. Kitada, A. Schimmer, et al., "The triterpenoid CDDO induces apoptosis in refractory CLL B cells, " Blood, vol. 100, no. 8, pp. 2965-2972, 2002.
393. S. Inoue, R. T. Snowden, M. J. S. Dyer, and G. M. Cohen, "CDDO induces apoptosis via the intrinsic pathway in lymphoid cells, " Leukemia, vol. 18, no. 5, pp. 948-952, 2004. (Pubitemid 38714619)
394. P. S. Brookes, K. Morse, D. Ray, et al., "The triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore, " Cancer Research, vol. 67, no. 4, pp. 1793-1802, 2007. (Pubitemid 46383407)
395. J. Eucker, K. Bangeroth, I. Zavrski, et al., "Ligands of peroxisome proliferator-activated receptor γ induce apoptosis in multiple myeloma, " Anti-Cancer Drugs, vol. 15, no. 10, pp. 955-960, 2004. (Pubitemid 39557482)
396. C. S. Mitsiades, N. Mitsiades, P. G. Richardson, S. P. Treon, and K. C. Anderson, "Novel biologically based therapies for Waldenstrom's macroglobulinemia, " Seminars in Oncology, vol. 30, no. 2, pp. 309-312, 2003. (Pubitemid 36506332)
397. T. Ikeda, Y. Nakata, F. Kimura, et al., "Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, " Molecular Cancer Therapeutics, vol. 3, no. 1, pp. 39-45, 2004. (Pubitemid 39193677)
398. D. Chauhan, G. Li, K. Podar, et al., "The bortezomib/ proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance, " Blood, vol. 103, no. 8, pp. 3158-3166, 2004. (Pubitemid 38451694)
399. K. Liby, N. Voong, C. R. Williams, et al., "The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells, " Clinical Cancer Research, vol. 12, no. 14, part 1, pp. 4288-4293, 2006.